Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Cash from Financing Activities: 2014-2025

Historic Cash from Financing Activities for Ascendis Pharma A (ASND) over the last 10 years, with Sep 2025 value amounting to $45.4 million.

  • Ascendis Pharma A's Cash from Financing Activities fell 90.33% to $45.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.5 million, marking a year-over-year decrease of 92.83%. This contributed to the annual value of $480.5 million for FY2024, which is 232.54% up from last year.
  • Ascendis Pharma A's Cash from Financing Activities amounted to $45.4 million in Q3 2025, which was up 474.81% from $7.9 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Cash from Financing Activities ranged from a high of $469.9 million in Q3 2024 and a low of -$23.6 million during Q4 2021.
  • In the last 3 years, Ascendis Pharma A's Cash from Financing Activities had a median value of $92,968 in 2024 and averaged $60.7 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 1,850,254.95% in 2022, then crashed by 573.35% in 2023.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's Cash from Financing Activities stood at -$23.6 million in 2021, then surged by 105.83% to $1.4 million in 2022, then plummeted by 573.35% to -$6.5 million in 2023, then surged by 101.43% to $92,968 in 2024, then tumbled by 90.33% to $45.4 million in 2025.
  • Its last three reported values are $45.4 million in Q3 2025, $7.9 million for Q2 2025, and -$19.0 million during Q1 2025.